These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36149726)

  • 21. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria.
    Guo DZ; Cheng JW; Yan JY; Huang A; Wang YP; Zhang SY; Cao Y; Huang XW; Fan J; Zhou J; Yang XR
    Ann Transl Med; 2022 Oct; 10(20):1091. PubMed ID: 36388794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease.
    Miao T; Lou X; Dong S; Zhang X; Guan W; Zhang Y; Li L; Yuan X; Ma D; Nan Y
    J Hepatocell Carcinoma; 2024; 11():145-157. PubMed ID: 38260867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Hepatol Res; 2022 Dec; 52(12):975-984. PubMed ID: 35976670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Yu MW; Lin CL; Liu CJ; Wu WJ; Hu JT; Huang YW
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma.
    Tomonari T; Sato Y; Tanaka H; Mitsuhashi T; Hirao A; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Takayama T
    JGH Open; 2021 Nov; 5(11):1275-1283. PubMed ID: 34816013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease.
    Lu H; George J; Eslam M; Villanueva A; Bolondi L; Reeves HL; McCain M; Chambers E; Ward C; Sartika D; Sands C; Maslen L; Lewis MR; Ramaswami R; Sharma R
    Liver Cancer; 2023 Feb; 12(1):19-31. PubMed ID: 36872928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
    Dong D; Shi JY; Shang X; Liu B; Xu WL; Cui GZ; Wang NY
    Medicine (Baltimore); 2022 Feb; 101(5):e28680. PubMed ID: 35119010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.
    Liu L; Xie S; Teng YX; Deng ZJ; Chen K; Liu HT; Huo RR; Liang XM; Guo PP; Yang DL; Ma L; Xiang BD; Li LQ; Zhong JH
    Front Oncol; 2021; 11():783339. PubMed ID: 35127490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should we undertake surveillance for HCC in patients with MAFLD?
    Norero B; Dufour JF
    Ther Adv Endocrinol Metab; 2023; 14():20420188231160389. PubMed ID: 37006779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.
    Lin YP; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Tsai MC
    Front Oncol; 2022; 12():816472. PubMed ID: 35186751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Vitale A; Svegliati-Baroni G; Ortolani A; Cucco M; Dalla Riva GV; Giannini EG; Piscaglia F; Rapaccini G; Di Marco M; Caturelli E; Zoli M; Sacco R; Cabibbo G; Marra F; Mega A; Morisco F; Gasbarrini A; Foschi FG; Missale G; Masotto A; Nardone G; Raimondo G; Azzaroli F; Vidili G; Oliveri F; Pelizzaro F; Ramirez Morales R; Cillo U; Trevisani F; Miele L; Marchesini G; Farinati F;
    Gut; 2023 Jan; 72(1):141-152. PubMed ID: 34933916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
    Camera S; Rimini M; Rossari F; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Salani F; Marseglia M; Amadeo E; Vitiello F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Iavarone M; Cabibbo G; Montes M; Foschi FG; Vivaldi C; Lonardi S; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Hiraoka A; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Persano M; Foti S; Piscaglia F; Scartozzi M; Cascinu S; Casadei-Gardini A
    Target Oncol; 2024 Jan; 19(1):29-39. PubMed ID: 38252195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy.
    Li X; Wang J; Ding X; Xu Y; Yu M; Wu H; Deng N; Li W; Chen J
    Front Pharmacol; 2022; 13():1032881. PubMed ID: 36703739
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study.
    Welland S; Leyh C; Finkelmeier F; Jefremow A; Shmanko K; Gonzalez-Carmona MA; Kandulski A; Jeliazkova P; Best J; Fründt TW; Djanani A; Pangerl M; Maieron A; Greil R; Fricke C; Sookthai D; Günther R; Schmiderer A; Wege H; Venerito M; Ehmer U; Müller M; Strassburg CP; Weinmann A; Siebler J; Waidmann O; Lange CM; Saborowski A; Vogel A
    Liver Cancer; 2022 Jun; 11(3):219-232. PubMed ID: 35949288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.
    Pan D; Liu HN; Yao ZY; Chen XX; Li YQ; Zhu JJ; Han ZX; Qin XB
    World J Gastrointest Oncol; 2024 Jun; 16(6):2504-2519. PubMed ID: 38994160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.